The Zenome Project is a decentralized blockchain-driven database of genomic information. This platform supports the possibility to manage your genomic data while maintaining privacy and ability to make a profit from selling access to different parts of the genome. It will establish equal conditions for drug development and for the progress of scientic and medical technologies.
ICO Status: Finished
Zenome project The Zenome Platform is going to raise awareness on genomic medicine, so users can make conscious decisions regarding their data. To ensure that, the Zenome Platform is based on the following fundamental principles. Individual ownership of personal genomic information User has all rights for personal genomic data. Freedom of choice User decides how genetic information should be used. The right to share User may grant access to genetic data to a third party in a way restricting data copying. Privacy Encryption prohibits access to genetic data without an explicit user's permission. System Architecture Simply put, Zenome platform is a P2P network. Some nodes are resource providers that store and process genetic information. Participants, analysts and service providers connect to distributed network and interact with each other. Data exchange is secured through encryption and utilization of blockchain smart contracts. Zenome platform main actors: Resource provider provides storage and CPU/GPU power for a reward. Participant uploads individual genetic data, gets reports and possibly uses genetic services. Analyst works with genetic information (a data scientist or a scientific organization) Service Provider implements a user-space genetic service (possibly paid) on the platform. Genome Tokenomics It appears that the exchange of genetic information is of crucial importance. The prospective genetic market must ensure protection from possible misuse and genetic discrimination in particular. It is particularly important to maintain transparency and equal access to this market. Zenome aims at creating the personal genomics infrastructure, that would enable participants to: - Upload genetic information and take control of it. - Securely store own genetic information. - Make profit by selling access to genetic data or part of it. - Undergo genetic testing in exchange to the right to use genetic information. - Get individual dietary recommendations or personal training program based on genetic makeup. - Make use of other genetic services. The principal customers of genetic information are companies interested in genetic targeting such as Google, Facebook, Unilever and pharmaceutical companies. Inside Zenome Platform different types of information are inextricably intertwined. The nature of each type determines the way to store information of that kind. Financial data, which includes records of transactions, is stored on blockchain. Anonymized genomic data is stored on the distributed network. Participant's personal data is kept on their own computers only. Treating data of different kind differently provides privacy as well as scalability of the system. Since all data transactions, including buying and selling data, are governed by smart-contracts, interactions can only include balances stored on blockchains. Using any of pre-existing tokens for this purpose would result in unreasonable dependence on the valuation of external token. Thus, a separate utility token should be issued to power economic interactions on the platform. Utility Token A platform's utility token, ZNA (Zenome DNA Token), powers Zenome's decentralized economics. The token is used as an exchange unit in the internal ecosystem. Value of ZNA depends directly on the success of the platform.
Get more information
|ICO token Distribution:
5% Team, 1% Marketing, 6.5% Zenome Fund, 25% ICO, 62.5% Frozen tokens
A platform's utility token, ZNA (Zenome DNA Token), powers Zenome's decentralized economics. The token is used as an exchange unit in the internal ecosystem. Value of ZNA depends directly on the success of the platform. ZNA is an utility token: ZNA is not evidence of ownership or right to control.
|There are no blockchain projects which are able to compete with Zenome.|
Initial Coin Offering
|Pre-ICO Launch: |
17th of October 2017
24th of October 2017
3rd of September 2018
17th of September 2018
ICO Tradable on Exchanges since:
still not tradable
|Platform: Ethereum (ERC20 Token)|
Team behind Zenome
Ph.D. in molecular biology and biochemistry Specialist in molecular biology and personal genomics. Alexey has a significant scientific background, expertise in business, and project management. In Zenome, Alexey is responsible for the overall vision and development of the business.
Ph.D. in bioinformatics Specialist in bioinformatics and mathematical biology, has experience of academic research and applied developments in the genome industry. Nikolay is a founder of a company developing new algorithms for genomic analysis.
Advisor, Molecular biologist, business development manager
Specialist in molecular genetics. Dmitry has a significant scientific background, expertise genetic analysis technologies, genomic and diagnostic markets, has successful business experience in biotechnology and Dx top intl companies.
Advisor, Entrepreneur, TED Speaker
Mr. Resnick served as Acting Chief Executive Officer of GenomeQuest, Inc. since September 2010 and Vice President of Software and Professional Services. He has extensive experience in building and growing innovative, sales-driven technology teams in the software and life science industries. Prior to joining GenomeQuest, he served as Chief Executive Officer of Harmony Line, Inc. Prior to Harmony Line, he spent over a decade in the sequence informatics industry, founding and selling Mosaic Bioinformatics in 1999 to NetGenics, Inc. He served as global bioinformatics software manager for Wyeth, and contributed to the Human Genome Project under Eric Lander at the MIT Whitehead
Advisor, Businessman and researcher in the field of life sciences
Dr. Nikolsky has 25 years of experience in life sciences, both business and research. Currently, he is CEO of Prosapia Genetics and an associated faculty at George Mason University in Virginia. In 2014-2016, he was CSO/director of Science at the BMT cluster at Skolkovo, the largest innovation fund in Russia. In 2010-2014. Yuri served as Vice President of R&D at Thomson Reuters (TR), a global information company, where he built a scientific consulting group working with major pharmaceutical companies on Big Data management and analysis. In 2003-2010 Dr. Nikolsky was CEO of GeneGo, a systems biology company acquired by Thomson Reuters in 2010. Prior to GeneGo, he was CEO of ChemDiv (San Diego, CA), a drug discovery CRO, turned into a fast growing pharmaceutical company. Dr. Nikolsky also co-founded Integrated Genomics, Inc. (Chicago, IL), a comparative genomics and bioinformatics company and held positions of a Senior Scientist for Thermogen, Inc. (Chicago, IL) and a scientist at the University of Chicago.
Visit zenome.io for more info.
Social stats of Zenome
- How TripAdvisor Destroyed Trust in the User Review - Dec 11, 2018
- Diamond Commodity Exchange CEDEX is Now Listed On Coinbene - Nov 28, 2018
- GALLACTIC ICO: The Next Generation Blockchain - Nov 19, 2018
- Giveaway: 10x UCIM Conference 2018, Singapore Tickets - Nov 15, 2018
- Unikrn has just gotten its crypto betting regulation - Nov 13, 2018
Know more than others on any Blockchain Party!
Join more than 5000 others to receive the breaking news and weekly summaries! No ICO spam, we promise.
You have Successfully Subscribed!
Categories:Initial Coin Offering